



European Federation of Pharmaceutical  
Industries and Associations



# Decentralised clinical trials, new directions


ACT-EU Workshop on Methodology Guidance, 23 November 2023



**Alison Bond, Director Global Regulatory  
and R&D Policy, Amgen**  
Acknowledging input from many industry  
colleagues



# Decentralised clinical trial model - bringing the trial to the participant



- Some or all of the assessments undertaken local to the participant or remotely
- The trial is organised around the participant & considers the needs of the site
- Providing options, reducing burden & facilitating participation
- Facilitating innovative, meaningful data collection & novel endpoints using Digital Health Technologies (DHTs)

## Challenges

- **Operational & Technology**
  - \* Data consolidation and complexity of data flows
  - \* Potential for selection bias
  - \* Impact on existing operations
  - \* Assessing service provider suitability & competency in DCTs
- **Responsibilities & oversight**
  - \* Participant - Investigator relationship
  - \* Investigator supervision of participants & distributed care team
  - \* Reporting and handling of potential AEs/SAEs
  - \* Site & participant training & acceptance of use of DCT elements
- **Data privacy/protection**
  - \* Maintaining privacy and protection of personal information
- **Data quality**
  - \* Comparability of data for site & remote assessments
  - \* Data acceptability & management of large data sets
- **Regulatory framework**
  - \* Emerging regulatory guidance globally - opportunity for further alignment
  - \* Fragmentation - adaption required according to local laws & regulations e.g. electronic signatures



Investigator Site



Mobile Healthcare Provider



Local Health Care Provider (HCP)



Telemedicine Platform



Participant Mobile App

# EU recommendation paper on decentralised elements in clinical trials

## Informing a harmonised approach

- Facilitates the use of decentralised elements in clinical trials, whilst protecting the rights, safety and well-being of participants and reliability of trial results.
- Provides an informative summary of how DCT elements can be incorporated, with the National Provisions Overview helpful for navigating across Member States.
- Evolution as new insights and experiences are gained is important, given the rapid advances in the field.

## Proposed topics for future updates

- **Locations that differ from traditional clinical trial site:** Expand broader than 'home' e.g. local Health Care Professional/ General Practitioner, local laboratories, mobile health units.
- **Data variability & acceptance:** How to measure differences between clinic and remote assessments, how to ensure data integrity & quality, regulator expectations.
- **Digital Health Technologies:** How to get DHT derived endpoints accepted faster, understanding key validation criteria, collection & use of participant data, expectations for availability of meaningful data.

# Considerations towards a shared future vision

---

**EU harmonisation:** Consider how the National Provisions Overview could be maintained and iterated upon in a timely manner, and made easily accessible.

*What efforts are ongoing on a local level to enable DCT elements to be implemented in EU countries where current local laws prohibit? Could we envision EU harmonisation?*

---

**Global alignment:** Consideration of future alignment/harmonisation with draft FDA guidance, and globally e.g. ICH E6(R3).

*How can we work towards global alignment/ harmonisation?*

---

**Building upon experience:** Sharing of experiences, lessons learnt & views is needed across stakeholders. Consider how to systematically evaluate the impact of DCT elements on data quality and integrity.

*What is needed to further explore the impact of DCT elements vs standard CTs? How can we further share experiences?*

---

**Future vision:** Decentralised elements become part of the clinical trial toolbox, deployed depending on the scientific question, patient population & needs, for patient-centric trials, more accessible to under-represented populations.

*All parties have the same aim - participant rights, safety & well-being, and data integrity for reliable trial results*





European Federation of Pharmaceutical  
Industries and Associations



# Thank you

